Men's Health

TrueNTH (True North) Peer Navigation is a new study that puts trained prostate cancer survivors and caregivers in touch with patients and caregivers looking for support. Peer navigators will help prostate cancer patients and caregivers navigate their journey through cancer care, from the point of diagnosis to treatment and beyond and will provide emotional, practical, and informational support. This work was awarded by Prostate Cancer Canada and is proudly funded by the Movember Foundation.

The primary purpose of our study is to examine the feasibility of using the ARESTM device to measure sleep parameters of PCa patients who are on ADT. In addition, we will also assess the feasibility of obtaining serial questionnaires from patients. In this small pilot study, we will describe subjective sleep quality, morphometric measures, urinary symptoms, hot flashes, and weight gain.

Recruitment Poster

Prostate Cancer Survivorship 360º is a collaboration-based initiative involving prostate cancer (PC) and survivorship researchers/clinicians from three Canadian prostate centers with the goal of identifying and tracking unmet supportive care needs of patients with localized PC and responding to these needs through survivorship care. The current randomized control trail (RCT) will focus on the development and evaluation of a facilitated electronic Prostate Cancer Survivorship Care Plan (PC-SCP).

99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and / or are candidates for active surveillance, but have planned to undergo radical prostatectomy. In these patients, the results may be used to help estimate the risk of a histopathologic Gleason grade of > 3+4. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 to detect clinically significant prostate cancer when compared to histopathology.

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.

The purpose of this study is to determine if the addition of JNJ-56021927 to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with low volume mHSPC.

The goal of this clinical research study is to learn if treatment with standard systemic therapy in combination with surgery or radiation therapy is more effective at controlling prostate cancer than standard systemic therapy alone. The safety of this treatment combination will also be studied.

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

The investigators aim to evaluate the feasibility of a larger clinical trial assessing an exercise program during the "teachable moment" in patients with prostate cancer and measuring its effect on tumor apoptosis signaling, lipogenesis and steroidogenesis. Participants will be randomized between a 8-12 week exercise program or to standard of care only. Participants will be assessed at screening, baseline (day 0), throughout the trial intervention (days 1-84), post-intervention visit (prior to radical prostatectomy) and final study visit 6-months post-radical prostatectomy.

Prostatitis is so widespread a disease that affects people from youths to seniors, with approximately a third experiencing a remission of symptoms over a year follow-up. Although the etiology of prostatitis is still not clear, it is mainly thought to be due to infection of bacteria or other microorganisms. Up to now, there is still no research being done on the microbiome (bacterial species) of the prostate. The objective of this study is to look at the etiology of chronic prostatitis (bacteria or non-bacteria prostatitis), mainly focusing on the effect of bacteria in the prostate.